Aisling Capital Management as of March 31, 2026
Portfolio Holdings for Aisling Capital Management
Aisling Capital Management holds 13 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Bridgebio Pharma (BBIO) | 79.4 | $378M | 5.1M | 74.26 | |
| Syndax Pharmaceuticals (SNDX) | 6.5 | $31M | 1.3M | 23.36 | |
| Monte Rosa Therapeutics (GLUE) | 5.4 | $26M | 1.6M | 16.45 | |
| Bicara Therapeutics (BCAX) | 2.4 | $11M | 569k | 19.89 | |
| BridgeBio Oncology Therapeutics Com New (BBOT) | 1.9 | $9.1M | 1.0M | 8.95 | |
| Compass Pathways Sponsored Ads (CMPS) | 1.7 | $7.9M | 1.4M | 5.53 | |
| Scholar Rock Hldg Corp (SRRK) | 0.8 | $3.8M | 77k | 49.16 | |
| Biomea Fusion (BMEA) | 0.7 | $3.1M | 2.0M | 1.53 | |
| Eupraxia Pharmaceuticals (EPRX) | 0.5 | $2.4M | 325k | 7.24 | |
| Urogen Pharma (URGN) | 0.4 | $1.9M | 108k | 17.98 | |
| Aclaris Therapeutics (ACRS) | 0.3 | $1.6M | 435k | 3.75 | |
| Marker Therapeutics Com New (MRKR) | 0.1 | $423k | 325k | 1.30 | |
| OnKure Therapeutics Com Cl A (OKUR) | 0.1 | $367k | 89k | 4.14 |
